pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 13·1 min read
save

Takeda to target 4,500 jobs as incoming CEO continues restructuring

Takeda will cut roughly 9% of its workforce over the next fiscal year as the next CEO puts her stamp on a yearslong restructuring. About 4,500 roles will be affected, the company said Wednesday in ...

May 13, 2026·read at Endpoints ↗

May 13, 2026 02:36 PM EDT Pharma Take­da to tar­get 4,500 jobs as in­com­ing CEO con­tin­ues re­struc­tur­ing Nicole DeFeudis Senior Reporter Take­da will cut rough­ly 9% of its work­force over the next fis­cal year as the next CEO puts her stamp on a years­long re­struc­tur­ing. About … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
81 words · retrieved May 13
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 2h agoNovartis' drug delivery deal with Alteogen; More worker cuts at CellaresEndpoints
  • 2h agoPfizer shares ADC rights with Medicus; RevMed updates lung cancer dataEndpoints
  • 3h agoAbbVie claims Phase 3 win for multiple myeloma drug etentamigEndpoints
  • 4h agoHealth tech investors are looking at bigger betsEndpoints
  • 6h agoSummit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialEndpoints